AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT04361708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: Oxaliplatin will be administered on day 1 of each cycle at 85mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
Study NCT04361708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel will be administered on day 1 of each cycle at 25mg at dose level 1; 37.5 at dose level 2. The drugs will be given through the patient's Mediport.It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
Study NCT04361708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: Leucovorin will be administered on day 1 of each cycle at 400mg/kg. The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
Study NCT04361708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irinotecan
Description: Irinotecan will be administered on day 1 of each cycle at 120mg/m2 for low risk group, 105mg/m2 for intermediate risk group, 45mg/m2 for high risk group . The drugs will be given through the patient's Mediport. It will be given once every 14 days (2 weeks), on days 1 and will be continued for 8 doses (4 months)
Study NCT04361708 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: 5-FU is given as a continuous intravenous infusion over 2 days. Patient can receive the 2-day infusion as an outpatient. On day 3 of each cycle, the patient will return to the infusion center to have the infusion hook-up disconnected.
Study NCT03406884 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: c-kit+ cells
Description: The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
Study NCT03406884 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: c-kit+ cells
Description: The autologous c-kit+ cells will be harvested from participant's right atrial tissue obtained from participant's SOC Norwood Operation. The harvested c-kit+ cells containing up to a total of 12,500 cells/kg will be delivered through 6-10 intramyocardial injections of approximately 100uL per injection for a total volume of approximately 0.6 mL.
Study NCT04083781 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Concizumab
Description: Concizumab will be administered daily subcutaneously (s.c., under the skin). When patients are randomised to concizumab prophylaxis they will receive a loading dose of 1.0 mg/kg concizumab at visit 2a (week 0: arm 2, 3 \& 4) or visit 9a (week 24: arm 1) followed by an initial daily dose of 0.20 mg/kg concizumab from treatment day 2. Within an initial 5-8-week dose adjustment period on 0.20 mg/kg concizumab, the patients can be increased or decreased in dose to 0.25 mg/kg or 0.15 mg/kg concizumab. A potential dose adjustment will take place at visit 4a.1 (week 6: arm 2, 3 \& 4) or 9a.3 (week 30: arm 1) and will be based on the concizumab exposure level measured at the previous visit 4a (week 4) or 9a.2 (week 28). Patients who have concizumab exposure levels of 200-4000 ng/mL will stay at 0.20 mg/kg concizumab. Patients in arm 1 will continue on-demand treatment with their usual bypassing product until visit 9a (week 24: end of main part for arm 1).
Study NCT04507412 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: dexamethasone
Description: perioperatively 9 mg i.v subministration
Study NCT03968679 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Unilateral elective nodal irradiation
Description: After injection of nanocolloid tracer submucosally around the tumor, patients undergo lymph drainage mapping (LDM) using SPECT/CT. If no contralateral drainage is visualized, the patient receives unilateral elective nodal irradiation (ENI). In case of contralateral lymph drainage, a contralateral sentinel node procedure is performed. If pathologic evaluation finds no metastasis, the patient receives unilateral ENI. If (micro/macro) metastasis are found, the patient will receive bilateral ENI.
Study NCT02360579 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Lifileucel
Description: A tumor sample is resected from each patient and cultured ex vivo to expand the population of tumor infiltrating lymphocytes. After lymphodepletion, patients are infused with Lifileucel followed by IL-2.
Study NCT03420170 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Conventional Physical Therapy
Description: Normal routine of physical therapy including mobility training, wheelchair skills, resistance exercise, aerobic training, balance exercise, functional exercise
Study NCT05023421 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: no intervention
Study NCT03757091 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Laryngoscopy
Description: Undergo video laryngoscopy
Study NCT03757091 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Tracheal Intubation
Description: Undergo flexible scope intubation
Study NCT03757091 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Tracheal Intubation
Description: Undergo flexible scope intubation
Study NCT03537963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: mHealth Stepped-care Intervention
Description: Test of the feasibility and acceptability of an mHealth stepped-care intervention for sleep disturbance in HCT survivors, to compare with the control group.
Study NCT02791425 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Brain Computer Interface (BCI) device
Description: A BCI system to facilitate communication in intubated patients. Patients use the device in the ICU for communication for 2 hours a day for 3 consecutive days.
Study NCT02791425 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Communication picture board
Description: The patient then uses a communication picture board for 2 hours a day for 3 consecutive days on the same days that the BCI device is used for comparison.
Study NCT03537963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Educational Control Condition
Description: General health education for cancer survivors provided in NCI booklets entitled Facing Forward: Life After Cancer Treatment and Coping With Advanced Cancer.
Study NCT03537963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Questionnaire
Description: After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
Study NCT03537963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: After the intervention, participants will be asked to complete a questionnaire to provide feedback on the intervention.
Study NCT03537963 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Interview
Description: Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
Study NCT03537963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Interview
Description: Qualitative interviews will be gathered after the participants have completed participation in the new intervention to gather data to inform future refinements of the intervention.
Study NCT03537963 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Qualitative Interviews
Description: To conduct qualitative interviews with patients, caregivers, and clinicians regarding sleep disturbance in HCT survivors and on preferences for a new mHealth intervention for sleep disturbance. Separate panels of 10 HCT survivors, 10 caregivers who were the primary caregiver of an HCT survivor during or after the inpatient HCT hospitalization, and 5-10 HCT clinicians will be recruited for individual qualitative interviews via telephone or in person.
Study NCT03537963 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Reality
Description: The intervention will comprise six 360º videos of relaxing natural landscapes from which patients can choose (i.e., beaches, tropical scenes, calm thunderstorms, snowfall). Participants will also choose an audio accompaniment: a progressive muscle relaxation script, a deep breathing exercise script, a mindfulness meditation script, or scene-relevant audio (e.g., waves crashing for the beach scene).
Study NCT02962401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Obinutuzumab
Description: 6 cycles every 28 days Cycle 1 :Obinutuzumab 1000mg I.V.(2 parts) 100mg day 1 and 900mg day 2 day 1, 8 and 15~Cycle 2 - 6 :~Obinutuzumab 1000mg I.V.day 1
Study NCT02962401 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Idelalisib
Description: 6 cycles every 28 days~Cycle 1 :~Idelalisib 150 mg x 2 p.o. day 1 to 28 Cycle 2 - 6 Idelalisib 150 mg x 2 p.o. day 1 to 28 Consolidation Idelalisib alone 150 mg twice a day until day 672 = 2 years after the beginning of the treatment
Study NCT01679288 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Ultrasound (Trademark:VScan; Manufacturer:General Electrics)
Description: Standardized measurements were made and aorta was tried to be visualized in its entirety, and a minimum of three hard copy images were obtained: upper transverse subxiphoid section, lower transverse section for distal view of aorta, and longitudinal section (with origin of celiac trunk or superior mesenteric artery), determining the maximum diameter in centimeters (cm).
Study NCT04505059 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Precision cardiac anesthesia
Description: Aperi-operative anesthetic management through target-controlled infusion to accurately control the patient blood concentration, with combination of bispectral index and neuromuscular monitoring to adjust the dosage of general anesthetics.
Study NCT04505059 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Conventional cardiac anesthesia
Description: The anesthesia strategy is mainly depending on the anesthesiologist's clinical experience
Study NCT02326623 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: distraction
Description: distraction using an iPad with a selection of child-appropriate games
Study NCT02326623 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: topical anesthetic cream
Description: standard care is to use a topical anesthetic cream at the site of planning IV access
Study NCT03323892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: second masturbation
Description: Husbands will be asked to produce a second sperm sample in the masturbatorium
Study NCT03323892 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: second masturbation
Description: Husbands will be asked to produce a second sperm sample in the masturbatorium
Study NCT00908986 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituximab
Description: 375mg/m2 q week x 4; repeated in 6 months
Study NCT05461859 — intervention group
Intervention type: PROCEDURE
Intervention: Cardioneuroablation (CNA) of the right anterior ganglionated plexus (RAGP)
Description: CNA of RAGP
Study NCT02649413 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prednisone
Description: Children with Idiopathic Nephrotic syndrome will start 60 mg/m2 prednisone.children that response in 8 days will receive an adjusted dose while the rest of the group will receive the 4 weeks usually dose.
Study NCT05400135 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Qungasvik (Tools for Life)
Description: The Qungasvik (toolbox) intervention is designed to build protection against alcohol use disorder (AUD) and suicide in Yup'ik Alaska Native youth 12-18 years old. The intervention is a community-driven and culturally-based process that develops and delivers 18-24 prevention activities leading to the two primary prevention variables, Reasons for Life and Reflective Processes about the Consequences of Alcohol Use and secondary prevention variables of multi-level protective factors and social networks.
Study NCT02361385 — intervention group
Intervention type: OTHER
Intervention: this is not an interventional study
Description: this is not an interventional study; this is a pilot feasibility study to see whether or not 11CPR28 will be taken up in joints of those known to have active arthritis clinically
Study NCT03084146 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 12-week elimination diet
Description: individualized 12-week elimination diet based on the 4 most reactive foods +/- a gluten-free diet if there is detection of positive anti- tissue transglutaminase (tTG) IgG and IgA and anti-deamidated gliadin peptide (DGP) IgG and IgA
Study NCT00984256 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atovaquone Proguanil
Description: Volunteers will receive doses of atovaquone/proguanil (Malarone) or matching sugar pills.
Study NCT00984256 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Procedure - malaria challenge
Description: 2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
Study NCT00984256 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Procedure - malaria challenge
Description: 2) Procedure- Malaria Challenge- Volunteers will be exposed to bites of infectious mosquitoes with the intention of causing malaria infection. Volunteers infected with malaria will undergo approved treatments for malaria.
Study NCT03737123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carboplatin
Description: Carboplatin AUC 4 IV Day 1 of each 21 day cycle
Study NCT03737123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gemcitabine
Description: Gemcitabine 1,000 mg/m2 IV Day 1 and Day 8 of each 21 day cycle
Study NCT03737123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Atezolizumab
Description: Atezolizumab 1,200 mg IV Day 1 of each 21 day cycle
Study NCT03737123 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Description: Docetaxel 75 mg/m2 IV Day 1 of each 21 day Cycle.
Study NCT04931940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Patients will receive the usual protein dosage at ≤1.2 g/kg/day for up to 28 days in the ICU
Study NCT04931940 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Higher Protein/Amino Acid Group
Description: Patients will receive high protein dosage at ≥2.2 g/kg/day for up to 28 days in the ICU
Study NCT00445549 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: 300 mg daily dose, 28 day cycle
Study NCT01572207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Immediate exercise
Description: Subjects in the immediate exercise group will be prescribed a home exercise program during the first meeting and will begin the 12 week training period immediately following the first meeting.
Study NCT01572207 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Delayed exercise
Description: Subjects in the delayed exercise group will begin the home exercise program 12 weeks following the initial meeting.
Study NCT03078114 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Spinal Manipulation
Description: The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to manipulate the spine.
Study NCT03078114 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Spinal Manipulation
Description: The subject will be asked to lay down and bend in a specific way. The clinician will apply force to certain areas to simulate manipulating the spine.
Study NCT01925560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Agave Inulin
Description: 3x3 Latin square with 3 periods
Study NCT01925560 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Placebo
Description: control- 0 (zero) grams/day inulin
Study NCT02669953 — intervention group
Intervention type: DRUG
Intervention: Aflibercept
Study NCT04416204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: glycogen loading
Description: Subjects will consume an isocaloric diet \[60% carbs, 20% protein, 20% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
Study NCT04416204 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: No Glycogen Loading
Description: Subjects will consume an isocaloric diet \[40% carbs, 20% protein, 40% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
Study NCT04545229 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: VR-based Pain Alleviation Tool (VR-PAT)
Description: Four smart phone based virtual reality games developed by the Research Information Solutions and Innovation (RISI) at the Nationwide Children's Hospital.
Study NCT03602612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 300 mg/m\^2 intravenous (IV) over 30 minutes on days -5, -4, and -3
Study NCT03602612 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine
Description: 30 mg/m\^2 intravenous (IV) infusion over 30 minutes administered immediately following the cyclophosphamide on day -5, -4, -3
Study NCT03602612 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Anti-B Cell Maturation Antigen (BCMA) chimeric antigen receptors (CARs) T cells
Description: 0.75x10\^6 - 12.0X10\^6 CAR+ T cells per kg of recipient bodyweight one time dose on day 0
Study NCT03080857 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Virtual Platform
Description: The platform will direct patients to review the Canadian Cardiovascular Guidelines and the Heart \& Stroke website for commonly asked questions relating to atrial fibrillation, as well as recommendations regarding nutrition and activity.
Study NCT03080857 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: AliveCor Heart Monitor
Description: A substudy of patients enrolled into the CSAF Tool study who own a compatible smart phone will be randomized to the Alive Cor Heart Monitor plus the virtual platform versus the virtual platform alone. The purpose of this substudy is to assess the feasibility and effect of incorporating Alive COR into a virtual online patient-education platform on patients' quality of life and AF-related emergency room visits and hospitalizations.
Study NCT00675181 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Melatonin
Description: 5mg per os
Study NCT00675181 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: per os
Study NCT04846829 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: saline PBO will be administered intravenously using established clinical procedures. A single dose if saline PBO will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
Study NCT04846829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: intermittent theta burst stimulation
Description: 10 sessions of treatment with cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~iTBS paradigm of a 2 s train repeated every 10 seconds
Study NCT04846829 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: intravenous citalopram hydrochloride (CIT)
Description: CIT will be administered intravenously using established clinical procedures. A single 40 mg dose of CIT diluted in 60 cc normal saline will be delivered intravenously under double-blind conditions via pump over a 40-minute period.
Study NCT04846829 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: continuous theta burst stimulation
Description: 10 sessions of treatment with iTBS to left or cTBS to right DLPFC TBS consists of three TMS pulses given at 50 Hz, with this triplet repeated at a frequency of 5 Hz (every 200 ms).~1800 pulses of cTBS will be delivered
Study NCT02592031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: XM17
Description: 300 IU corresponds to an injection volume of 0.5 mL.
Study NCT02592031 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gonal-f®
Description: 300 IU corresponds to an injection volume of 0.5 mL.
Study NCT02592031 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zoladex®
Description: 3.6 mg
Study NCT01364896 — intervention group
Intervention type: PROCEDURE
Intervention: Venous blood samples, anal swab samples, vaginal swab samples, high resolution anoscopy (HRA), anal biopsy samples
Description: Before and at least 6 months after starting a new non-steroid immunosuppressive agent for IBD treatment, eligible participants who are attending for routine colonoscopy will have:~1. Anal swab samples (and vaginal swab samples for female participants) for human papillomavirus PCR typing (6, 11, 16, 18, 31, 33, 45, 52, 58)~2. High-resolution anoscopy and biopsy of all visible high-grade dysplastic lesions based on validated colposcopic criteria~3. Anal cytology testing
Study NCT02153593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic Acid
Description: 1g intra-articular before closing the wound surgery
Study NCT02153593 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fibrin glue
Description: 5mL intra-articular before closing the wound surgery
Study NCT02153593 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrocauterization
Description: Coagulation blood from vessels by means of a electrocautery
Study NCT02153593 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electrocauterization
Description: Coagulation blood from vessels by means of a electrocautery